Cystic fibrosis medication levels during pregnancy and breastfeeding
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how CFTR modulator medications (used to treat cystic fibrosis) behave in your body during pregnancy and while breastfeeding. The goal is to understand how much of the medication passes into breast milk and whether doses need to be adjusted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with cystic fibrosis.
- You are taking a cystic fibrosis medication called a CFTR modulator (such as Trikafta, Symdeko, or Orkambi) during pregnancy or after giving birth.
- You are able to breastfeed and plan to do so.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with cystic fibrosis (CF) during pregnancy and after birth, and checks on their babies and young children. The goal is to learn more about how CF affects pregnancy and child development.
This study looks at how the cystic fibrosis medication Kaftrio works during pregnancy and after childbirth. It follows women with cystic fibrosis who are already taking Kaftrio and their newborn babies.
This study tracks the natural course of cystic fibrosis in young children (under 6) and healthy babies over time. It aims to understand how the disease changes in the era of modern treatments, which could help improve care and guide future therapies.
This study looks at how cystic fibrosis care is organized when patients take highly effective CFTR modulator drugs. It aims to understand if care needs change for those on modulators compared to those who cannot take them.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.